title: Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.
abstract: Rivaroxaban is a once-daily oral anticoagulant currently marketed for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. This indication is largely based on the results of the ROCKET-AF trial. Although these results are robust, studies performed in clinical practice are necessary to confirm these data in real-life patients. These studies have shown rates of stroke and bleeding similar to that found in ROCKET-AF. As an anticoagulant, attention should be paid to making a correct prescription of rivaroxaban, particularly in fragile patients, to reduce the risk of bleeding. In addition, a number of studies have shown that rivaroxaban is cost-effective in clinical practice. Moreover, rivaroxaban is a good alternative to warfarin in patients undergoing elective cardioversion or atrial fibrillation ablation.
authors: Coordinador de Área. Servicio de Cardiología Hospital Universitario Virgen del Rocío. Universidad de Sevilla, Sevilla, Spain.
authors: Gonzalo
authors: G
authors: Barón-Esquivias
authors: Francisco
authors: F
authors: Fernández-Avilés
authors: Felipe
authors: F
authors: Atienza
authors: Pablo
authors: P
authors: Pastor Pueyo
authors: Rocío
authors: R
authors: Toro
authors: Marcelo
authors: M
authors: Sanmartín Fernández
mesh_terms: D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D017115:Catheter Ablation; D004554:Electric Countershock; D065427:Factor Xa Inhibitors / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D000069552:Rivaroxaban / Q000627:therapeutic use*; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D065427:Factor Xa Inhibitors; D000069552:Rivaroxaban
keywords: ROCKET-AF; atrial fibrillation; bleeding; clinical practice; real-life; rivaroxaban; stroke